Remimazolam is an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, currently in Phase III clinical development in the U.S. for procedural sedation.
In the human body, Remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. Like other benzodiazepines, Remimazolam can be reversed with flumazenil to rapidly terminate sedation and anesthesia if necessary. Remimazolam is being studied in colonoscopy, bronchoscopy and other general anesthesia procedures for its rapid onset and offset of action as well as its cardio-respiratory safety profile.
The U.S. commercialization rights to Remimazolam were licensed to Cosmo Pharmaceuticals, NV from PAION UK based in Cambridge, UK, an affiliate of PAION AG, Germany.